with a normal P/E . Some underperforming restaurants need to close.
What a STUPID company MSFT is!
in line with other restaurants of single digit growth.
to put its P/E in line with other restaurant stocks of similar growth.
What the hell Kalydeco cure? NOTHING.
and almost no plan will cover so the wait is on for PQRQ to use a gene therapy mist to actually cure CF, not just a little better breathing with Kalydeco.
who simply would not be buying any of it at $84,000 per patient and Sovaldi offers a cure for Hep. C., not just a few more months like all the prostate drugs.
and insurance is only buying the cheapest, that is Zytiga. Even that is too expensive so they are waiting for the generic version next year.
Imperial applied for a permit to increase outflow from this mini-lake which is non-toxic. Heavy rains flow in and outflow needs to be increased. This is not the traditional pond for tailings.
so it doesn't have to pay UCLA, the inventor of its half drug, a single dime. All the profits flow to the CEO and officers, in terms of $Billions, not the shareholders.
The only earnings killed are the royalties promised to the inventor of Xtandi, that is UCLA. Not a dime in the report. UCLA should foreclose.
WAG already owns 45% of Boots so buying the rest in a great company it knows is a no brainer. The pricing power of this combined entity will be unbeatable.
It is still fast tracked in U.S. for Non-T.B. infections. The other study for CF patients is a bonus.